Bristol-Myers Squibb to Acquire Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and Amira Pharmaceuticals, Inc., announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire privately held Amira Pharmaceuticals, a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
FDA approves new medicine BRILINTA (ticagrelor) for use in the US
- Details
- Category: AstraZeneca
AstraZeneca announced that the US Food and Drug Administration (FDA) has approved BRILINTA (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.
Pfizer To Acquire Icagen
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Icagen, Inc. (Nasdaq: ICGN) have entered into a definitive merger agreement. Pfizer, which currently owns approximately 11% of Icagen's fully diluted shares, will acquire the remaining 8.3 million shares at a price of $6.00 per share.
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) reported the outcome of the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee meeting on the New Drug Application for the investigational compound dapagliflozin.
Novartis delivers strong financial results and four major approvals
- Details
- Category: Novartis
Novartis' net sales rose 27% (+19% cc) to USD 14.9 billion. Currency benefited sales by 8% as the US dollar weakened against most currencies. Recently launched products grew 46% over the previous-year quarter, contributing USD 3.8 billion to total net sales for the Group.
Abbott Confirms Long-Term Commitment to HIV Care
- Details
- Category: Abbott
Abbott plans to develop two new formulations of its HIV medicines, Kaletra (lopinavir/ritonavir) and Norvir (ritonavir), to offer new formulation options for people living with HIV-1. The company is currently investigating a new powder formulation of Norvir as well as a co-formulation of three HIV medicines - lopinavir, ritonavir and 3TC (lamivudine).
Novartis begins shipment of Fluvirin® seasonal influenza vaccine to US customers
- Details
- Category: Novartis
Novartis has started shipping seasonal influenza vaccine to its US customers for the 2011-2012 influenza season. Early delivery of seasonal influenza vaccine will ensure healthcare professionals have the ability to provide the earliest possible protection against influenza.
More Pharma News ...
- XGEVA® (Denosumab) Granted Marketing Authorization in the European Union
- Roche provides update from FDA hearing on Avastin for metastatic breast cancer
- Lilly CEO Says Biopharmaceuticals Should Be Included in Transatlantic Trade and Economic Discussions
- Sanofi Reports Positive Top-Line Results from First Phase 3 Study of Alemtuzumab in Multiple Sclerosis
- Boehringer Ingelheim and Ashoka's Changemakers Launch "Making More Health" Competition
- Phase III trial of Novartis drug Afinitor® met primary endpoint
- Pfizer to Explore Strategic Alternatives for its Animal Health and Nutrition Businesses